HUTCHMED (China) 将来の成長

Future 基準チェック /36

HUTCHMED (China)利益と収益がそれぞれ年間14.5%と15%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に12.2% 11.1%なると予測されています。

主要情報

14.5%

収益成長率

11.10%

EPS成長率

Pharmaceuticals 収益成長	11.0%
収益成長率	15.0%
将来の株主資本利益率	12.18%
アナリストカバレッジ	Good
最終更新日	13 May 2025

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

SHSC:13 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	1,004	166	109	132	18
12/31/2026	844	108	20	44	24
12/31/2025	699	310	276	251	22
12/31/2024	630	38	-17	0	N/A
9/30/2024	621	-2	-41	-23	N/A
6/30/2024	611	-42	-65	-47	N/A
3/31/2024	724	29	61	86	N/A
12/31/2023	838	101	187	219	N/A
9/30/2023	798	36	95	133	N/A
6/30/2023	757	-29	2	48	N/A
3/31/2023	592	-195	-151	-110	N/A
12/31/2022	426	-361	-305	-269	N/A
9/30/2022	414	-308	-276	-246	N/A
6/30/2022	401	-255	-246	-223	N/A
3/31/2022	376	-235	-245	-227	N/A
12/31/2021	356	-195	-221	-204	N/A
9/30/2021	317	-187	-169	-155	N/A
6/30/2021	279	-178	-118	-105	N/A
3/31/2021	258	-151	-95	-83	N/A
12/31/2020	228	-126	-70	-62	N/A
9/30/2020	221	-117	-72	-63	N/A
6/30/2020	209	-110	-88	-79	N/A
3/31/2020	204	-102	-63	-54	N/A
12/31/2019	205	-106	-89	-81	N/A
9/30/2019	205	-93	-86	-77	N/A
6/30/2019	214	-87	-52	-44	N/A
3/31/2019	214	-83	-37	-31	N/A
12/31/2018	214	-75	-39	-33	N/A
9/30/2018	218	-72	N/A	-33	N/A
6/30/2018	217	-61	N/A	-47	N/A
3/31/2018	230	-39	N/A	-49	N/A
12/31/2017	241	-27	N/A	-9	N/A
9/30/2017	240	-7	N/A	-4	N/A
6/30/2017	238	13	N/A	1	N/A
3/31/2017	227	12	N/A	-4	N/A
12/31/2016	216	12	N/A	-10	N/A
9/30/2016	200	38	N/A	2	N/A
6/30/2016	200	-8	N/A	-1	N/A
3/31/2016	189	-22	N/A	-5	N/A
12/31/2015	178	-35	N/A	-9	N/A
9/30/2015	168	-80	N/A	-11	N/A
6/30/2015	139	-66	N/A	-6	N/A
3/31/2015	113	-50	N/A	1	N/A
12/31/2014	87	-35	N/A	8	N/A
9/30/2014	72	-20	N/A	11	N/A
6/30/2014	59	7	N/A	21	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 13の予測収益成長率 (年間14.5% ) は貯蓄率 ( 2.6% ) を上回っています。

収益対市場: 13の収益 ( 14.5% ) はHong Kong市場 ( 10.5% ) よりも速いペースで成長すると予測されています。

高成長収益: 13の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 13の収益 ( 15% ) Hong Kong市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: 13の収益 ( 15% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 13の自己資本利益率は、3年後には低くなると予測されています ( 12.2 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/21 17:03
終値	2025/05/21 00:00
収益	2024/12/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

HUTCHMED (China) Limited 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。48

アナリスト	機関
Alec Stranahan	BofA Global Research
John Newman	Canaccord Genuity
Adam McCarter	Cavendish

HUTCHMED (China) 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

HUTCHMED (China) Limited Provides Consolidated Revenue Guidance for the Year 2025

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Recent updates

HUTCHMED (China) Limited to Present Data from Several Studies of Compounds Discovered at the Upcoming American Association of Cancer Research Annual Meeting 2025

HUTCHMED (China) Limited Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED (China) Limited Provides Consolidated Revenue Guidance for the Year 2025

HUTCHMED (China) Limited Announces NMPA Conditional Approval for Tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED (China) Limited Announces Board and Committee Changes

HUTCHMED (China) Limited, Annual General Meeting, May 13, 2025

HUTCHMED (China) Limited Completes Enrollment of A Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED (China) Limited Announces Appointment of Independent Non-Executive Director and Member of Board Committee

HUTCHMED (China) Limited to Report Fiscal Year 2024 Results on Mar 19, 2025

Hutchmed Announces NMPA Full Approval for Orpathys (Savolitinib) in China for Patients with Locally Advanced or Metastatic Met Exon 14 NSCLC

HUTCHMED (China) Limited Announces NDA Acceptance in China with Priority Review Status for ORPATHYS®? and TAGRISSO®? Combination in Lung Cancer Patients with MET amplication After Progression on First-Line EGFR Inhibitor Therapy

Hutchmed (China) Limited Announces Breakthrough Therapy Designation in China for Orpathys®? and Tagrisso®? Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

Investor sentiment improves as stock rises 16%

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Investor sentiment improves as stock rises 20%

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021)

CFO & Executive Director recently sold HK$22m worth of stock

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021)

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

Less than half of directors are independent

Now 22% undervalued after recent price drop

Now 26% undervalued after recent price drop

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想